We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to Amneal (AMRX) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Read MoreHide Full Article
Wall Street analysts expect Amneal Pharmaceuticals (AMRX - Free Report) to post quarterly earnings of $0.07 per share in its upcoming report, which indicates a year-over-year decline of 69.6%. Revenues are expected to be $630.67 million, up 3.4% from the year-ago quarter.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some Amneal metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts expect 'Net Revenue- Generics Segment' to come in at $397.87 million. The estimate suggests a change of -0.3% year over year.
The average prediction of analysts places 'Net Revenue- AvKARE Segment' at $125.44 million. The estimate indicates a change of +16.1% from the prior-year quarter.
It is projected by analysts that the 'Net Revenue- Specialty Segment' will reach $107.38 million. The estimate indicates a change of +4.7% from the prior-year quarter.
Shares of Amneal have experienced a change of +1% in the past month compared to the +3.8% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), AMRX is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Countdown to Amneal (AMRX) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Wall Street analysts expect Amneal Pharmaceuticals (AMRX - Free Report) to post quarterly earnings of $0.07 per share in its upcoming report, which indicates a year-over-year decline of 69.6%. Revenues are expected to be $630.67 million, up 3.4% from the year-ago quarter.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some Amneal metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts expect 'Net Revenue- Generics Segment' to come in at $397.87 million. The estimate suggests a change of -0.3% year over year.
The average prediction of analysts places 'Net Revenue- AvKARE Segment' at $125.44 million. The estimate indicates a change of +16.1% from the prior-year quarter.
It is projected by analysts that the 'Net Revenue- Specialty Segment' will reach $107.38 million. The estimate indicates a change of +4.7% from the prior-year quarter.
View all Key Company Metrics for Amneal here>>>
Shares of Amneal have experienced a change of +1% in the past month compared to the +3.8% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), AMRX is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>